GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts give GH Research a consensus "Moderate Buy" rating (9 buys, 1 hold, 1 sell) with an average 12‑month target of about $40.13, and several firms recently raised price targets (e.g., HC Wainwright to $70).
• The stock trades around $15.72 with a market cap near $975 million and a 1‑year range of $8.45–$19.51, while institutional investors own about 56.9% of shares and several funds (Avoro, RTW) recently added sizable stakes.
• GH Research is a clinical‑stage biotech developing psychedelic‑inspired treatments based on 5‑MeO‑DMT (lead program GH001 for treatment‑resistant depression) and recently reported quarterly EPS of ($0.23), beating estimates by $0.06.

Shares of GH Research PLC (NASDAQ:GHRS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eleven research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $40.1250.

A number of equities analysts recently issued reports on the company. Citigroup reissued a "market outperform" rating on shares of GH Research in a report on Tuesday, January 6th. HC Wainwright increased their price objective on GH Research from $35.00 to $70.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Citizens Jmp lifted their target price on GH Research from $39.00 to $42.00 and gave the company a "market outperform" rating in a research note on Friday, March 6th. Needham & Company LLC boosted their target price on GH Research from $31.00 to $32.00 and gave the company a "buy" rating in a report on Friday, March 6th. Finally, Guggenheim set a $34.00 price target on GH Research and gave the stock a "buy" rating in a research note on Tuesday, March 10th.

Hedge Funds Weigh In On GH Research

Large investors have recently bought and sold shares of the company. Avoro Capital Advisors LLC acquired a new stake in shares of GH Research in the 4th quarter worth $22,860,000. XTX Topco Ltd acquired a new position in shares of GH Research during the fourth quarter worth about $564,000. Virtus Investment Advisers LLC increased its stake in shares of GH Research by 130.1% during the fourth quarter. Virtus Investment Advisers LLC now owns 20,408 shares of the company's stock worth $259,000 after acquiring an additional 11,539 shares during the period. Squadron Capital Management LLC purchased a new position in GH Research during the fourth quarter worth about $4,000,000. Finally, RTW Investments LP raised its holdings in GH Research by 6.5% during the fourth quarter. RTW Investments LP now owns 5,933,815 shares of the company's stock worth $75,359,000 after purchasing an additional 364,251 shares in the last quarter. Hedge funds and other institutional investors own 56.90% of the company's stock.

GH Research Price Performance

Shares of NASDAQ:GHRS opened at $15.72 on Friday. The stock has a market cap of $975.11 million, a P/E ratio of -19.65 and a beta of 1.00. The firm has a fifty day moving average price of $15.02 and a 200 day moving average price of $14.48. GH Research has a 1-year low of $8.45 and a 1-year high of $19.51.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings data on Friday, March 6th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.06. Sell-side analysts expect that GH Research will post -0.8 EPS for the current fiscal year.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm's lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.